$0.71
0.00 (-0.37%)
Open$0.68
Previous Close$0.71
Day High$0.75
Day Low$0.67
52W High$1.58
52W Low$0.63
Volume—
Avg Volume208.1K
Market Cap8.38M
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,831.1% upside
Current
$0.71
$0.71
Target
$27.73
$27.73
$20.43
$27.73 avg
$35.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.57M | 1.60M | 1.25M |
| Net Income | 4.2K | 5.8K | 3.4K |
| Profit Margin | 0.3% | 0.4% | 0.3% |
| EBITDA | 8.2K | 8.5K | 6.5K |
| Free Cash Flow | 4.7K | 4.2K | 2.8K |
| Rev Growth | -8.5% | +15.0% | -6.0% |
| Debt/Equity | 0.92 | 0.88 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |